Modelos de datos seleccionados

Debe iniciar sesión para seleccionar modelos de datos para descargar o realizar un análisis.

62 Resultados de la búsqueda.
Relevancia Evaluación Nuevo primero Antiguo primero

Gastrointestinal Stromal Tumor NCT00324987 - Off Treatment Notice Gastrointestinal Stromal Tumor S0502 NCT00324987

- 24/03/15 - 1 formulario, 2 itemgroups, 28 items, 1 idioma
Itemgroups: Header, OFF TREATMENT
S0502 Off Treatment Notice S0502 Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor NCT00324987 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=FCCFD537-4859-4344-E034-0003BA3F9857

Gastrointestinal Stromal Tumor NCT00324987 Toxicity - S0502 Adverse Event Form - 2320351v1.0 - S0502 Adverse Event Form

- 09/01/15 - 1 formulario, 3 itemgroups, 19 items, 1 idioma
Itemgroups: Header, Adverse Events, Comments
S0502 Adverse Event Form S0502 Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=FCBF7FD7-A1A5-7312-E034-0003BA3F9857

Gastrointestinal Stromal Tumor NCT00324987 Follow-Up - S0502 Follow Up Form - 2321009v1.0 - S0502 Follow Up Form

- 09/01/15 - 1 formulario, 3 itemgroups, 27 items, 1 idioma
Itemgroups: Header, VITAL STATUS, Comments
S0502 Follow Up Form S0502 Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=FCCFE232-103D-44EC-E034-0003BA3F9857

Gastrointestinal Stromal Tumor NCT00324987 Treatment - S0502 Cycle-Specific Treatment Form - 2320335v1.0 - S0502 Cycle-Specific Treatment Form

- 09/01/15 - 1 formulario, 4 itemgroups, 28 items, 1 idioma
Itemgroups: Header, Status, Treatment for this Cycle, Comments
S0502 Cycle-Specific Treatment Form S0502 Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=FCBF7C37-6B6E-72A0-E034-0003BA3F9857

Southwest Oncology Group Registration Form (S0502) NCT00324987

- 20/09/21 - 1 formulario, 3 itemgroups, 38 items, 1 idioma
Itemgroups: Header, Patient demographics, Miscellaneous Patient Information
Southwest Oncology Group Registration Form (S0502) NCT00324987 S0502 Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=398EB7EC-7565-1438-E044-0003BA3F9857

WTZ-GIST-09-01 (Imatinib + LBH589) Dosage administration record 2009-011417-24 DRKS00000657 - WTZ-GIST-09-01 (Imatinib + LBH589) Dosage administration record 2009-011417-24

- 15/12/16 - 1 formulario, 2 itemgroups, 20 items, 1 idioma
Itemgroups: Dosage administration, Contribution of study medication
Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors WTZ-GIST-09-01 (EudraCT number: 2009-011417-24; German Clinical Trials Register: DRKS00000657) was approved by the institutional ethics committees of the two participating centers and the German Federal Regulatory Drug Agency (BfArM; 4035954).

WTZ-GIST-09-01 (Imatinib + LBH589) Follow-Up 2009-011417-24 DRKS00000657 - WTZ-GIST-09-01 (Imatinib + LBH589) Follow-Up 2009-011417-24

- 02/12/16 - 1 formulario, 1 itemgroup, 14 items, 1 idioma
Itemgroup: Follow Up
Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors WTZ-GIST-09-01 (EudraCT number: 2009-011417-24; German Clinical Trials Register: DRKS00000657) was approved by the institutional ethics committees of the two participating centers and the German Federal Regulatory Drug Agency (BfArM; 4035954).

WTZ-GIST-09-01 (Imatinib + LBH589) Final Medical Examination 2009-011417-24 DRKS00000657 - WTZ-GIST-09-01 (Imatinib + LBH589) Final Medical Examination 2009-011417-24

- 02/12/16 - 1 formulario, 1 itemgroup, 16 items, 1 idioma
Itemgroup: Final medical examination
Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors WTZ-GIST-09-01 (EudraCT number: 2009-011417-24; German Clinical Trials Register: DRKS00000657) was approved by the institutional ethics committees of the two participating centers and the German Federal Regulatory Drug Agency (BfArM; 4035954).

WTZ-GIST-09-01 (Imatinib + LBH589) End of study report 2009-011417-24 DRKS00000657 - WTZ-GIST-09-01 (Imatinib + LBH589) End of study report 2009-011417-24

- 02/12/16 - 1 formulario, 3 itemgroups, 10 items, 1 idioma
Itemgroups: End of study report, Premature end of study, Date
Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors WTZ-GIST-09-01 (EudraCT number: 2009-011417-24; German Clinical Trials Register: DRKS00000657) was approved by the institutional ethics committees of the two participating centers and the German Federal Regulatory Drug Agency (BfArM; 4035954).

WTZ-GIST-09-01 (Imatinib + LBH589) Concomitant Therapies 2009-011417-24 DRKS00000657 - WTZ-GIST-09-01 (Imatinib + LBH589) Concomitant Therapies 2009-011417-24

- 02/12/16 - 1 formulario, 1 itemgroup, 8 items, 1 idioma
Itemgroup: Concomitant Therapies
Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors WTZ-GIST-09-01 (EudraCT number: 2009-011417-24; German Clinical Trials Register: DRKS00000657) was approved by the institutional ethics committees of the two participating centers and the German Federal Regulatory Drug Agency (BfArM; 4035954).

WTZ-GIST-09-01 (Imatinib + LBH589) Tumor Evaluation 2009-011417-24 DRKS00000657 - WTZ-GIST-09-01 (Imatinib + LBH589) Tumor Evaluation 2009-011417-24

- 02/12/16 - 1 formulario, 1 itemgroup, 5 items, 1 idioma
Itemgroup: Low-Dose PET-CT
Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors WTZ-GIST-09-01 (EudraCT number: 2009-011417-24; German Clinical Trials Register: DRKS00000657) was approved by the institutional ethics committees of the two participating centers and the German Federal Regulatory Drug Agency (BfArM; 4035954).

WTZ-GIST-09-01 (Imatinib + LBH589) Tumor evaluation RECIST Day 57 2009-011417-24 DRKS00000657 - WTZ-GIST-09-01 (Imatinib + LBH589) Tumor evaluation RECIST Day 57 2009-011417-24

- 02/12/16 - 1 formulario, 4 itemgroups, 18 items, 1 idioma
Itemgroups: Target Lesion, Non-Target-Lesions, New Lesions, RECIST Criteria
Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors WTZ-GIST-09-01 (EudraCT number: 2009-011417-24; German Clinical Trials Register: DRKS00000657) was approved by the institutional ethics committees of the two participating centers and the German Federal Regulatory Drug Agency (BfArM; 4035954).

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial